Vasoactive pharmacologic therapy in cardiogenic shock: a critical review

References

• Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726–1734.
   PubMed Web of Science ®Google Scholar
• Gamper G, Havel C, Arrich J, et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2016;2(2):CD003709.
   PubMedGoogle Scholar
• Sakr Y, Reinhart K, Vincent JL, et al. Does dopamine administration in shock influence outcome? Results of the sepsis occurrence in acutely ill patients (SOAP) study. Crit Care Med. 2006;34(3):589–597.
   PubMed Web of Science ®Google Scholar
• Esteban A, Frutos-Vivar F, Ferguson ND, et al. Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Crit Care Med. 2007;35(5):1284–1289.
   PubMed Web of Science ®Google Scholar
• Alberti C, Brun-Buisson C, Chevret S, et al. Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med. 2005;171(5):461–468.
   PubMed Web of Science ®Google Scholar
• Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287–1296.
   PubMed Web of Science ®Google Scholar
• Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005;294(4):448–454.
   PubMed Web of Science ®Google Scholar
• Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. 1999;341(9):625–634.
   PubMed Web of Science ®Google Scholar
• Schumann J, Henrich EC, Strobl H, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2018;1(1):CD009669.
   PubMedGoogle Scholar
• van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American heart association. Circulation. 2017;136(16):e232–e268.
   PubMed Web of Science ®Google Scholar
• Squara P, Hollenberg S, Payen D. Reconsidering vasopressors for cardiogenic shock: everything should be made as simple as possible, but not simpler. Chest. 2019;156(2):392–401.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
   PubMed Web of Science ®Google Scholar
• Amado J, Gago P, Santos W, et al. Cardiogenic shock: inotropes and vasopressors. Choque cardiogénico – fármacos inotrópicos e vasopressores. Rev Port Cardiol. 2016;35(12):681–695.
   PubMedGoogle Scholar
• Shaffer A, Sheikh O, Prasad A. Cardiogenic shock: a systematic review of clinical trials registered with clinicaltrials.gov. J Invasive Cardiol. 2020;32(4):E86–E96.
   PubMed Web of Science ®Google Scholar
• Maharaj R, Metaxa V. Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials. Crit Care. 2011;15(3):R140.
   PubMed Web of Science ®Google Scholar
• Goldberg RJ, Samad NA, Yarzebski J, et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med. 1999;340(15):1162–1168.
   PubMed Web of Science ®Google Scholar
• Kolte D, Khera S, Aronow WS, et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. JAHA. 2014;3(1):e000590.
   Google Scholar
• Ibanez B, James S, Agewall S, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC. Eur Heart J. 2017;39(2):119–177.
   Web of Science ®Google Scholar
• van Diepen S. Norepinephrine as a first-line inopressor in cardiogenic shock: oversimplification or best practice? J Am Coll Cardiol. 2018;72(2):183–186.
   PubMed Web of Science ®Google Scholar
• Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: this document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv. 2019;94(1):29–37.
   PubMed Web of Science ®Google Scholar
• Léopold V, Gayat E, Pirracchio R, et al. Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Med. 2018;44(6):847–856.
   PubMed Web of Science ®Google Scholar
• Thiele H, Ohman EM, de Waha-Thiele S, et al. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J. 2019;40(32):2671–2683.
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice. Circulation. 2013;127(4):e362–e425.
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139–e228.
   PubMed Web of Science ®Google Scholar
• Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.
   PubMed Web of Science ®Google Scholar
• Moher D, Jadad AR, Nichol G, et al. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials. 1995;16(1):62–73.
   PubMedGoogle Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
   PubMedGoogle Scholar
• Clark HD, Wells GA, Huët C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials. 1999;20(5):448–452.
   PubMedGoogle Scholar
• Wolfson C, Perrault A, Demers L, et al. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer’s disease drug trials. Dement Geriatr Cogn Disord. 2001;12(3):232–236.
   PubMed Web of Science ®Google Scholar
• Olivo SA, Macedo LG, Gadotti IC, et al. Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther. 2008;88(2):156–175.
   PubMed Web of Science ®Google Scholar
• Coma CI, López-Sendón J. Efecto hemodinámico de la dobutamina en el shock cardiogénico [Hemodynamic effect of dobutamine in cardiogenic shock]. Rev Esp Cardiol. 1981;34(6):483–489. ‐
   PubMedGoogle Scholar
• Aroński A, Kübler A, Sliwinski M, et al. Die Anwendung von Dopamin bei schock und Herzinsuffizienz [The use of dopamin in shock and heart failure (author's transl)]. Anaesthesist. 1978;27(4):183–186.
   PubMedGoogle Scholar
• Belskii NE, Pilipenko VA, Roshchin SI, Shira AI, et al. Use of nitroglycerin in the treatment of acute heart failure and cardiogenic shock in patients with myocardial infarction. Cor Vasa. 1987;29(2):89–97.
   PubMed Web of Science ®Google Scholar
• Iversen S, Mayer E, Hake U, et al. Efficacy of phosphodiesterase inhibitor enoximone in management of postcardiotomy cardiogenic shock. Scand J Thorac Cardiovasc Surg. 1992;26(2):143–149.
   PubMed Web of Science ®Google Scholar
• Nathan CR, Dowling LE. S. Dopamine versus norepinephrine in the treatment of shock. CJEM. 2011;13(6):395–397.
   PubMedGoogle Scholar
• Bahloul M, Tounsi A, Ben Algia N, et al. Does change of catecholamine use improve the outcome of patients with shock admitted to intensive care unit? Am J Ther. 2014;21(5):358–365.
   PubMed Web of Science ®Google Scholar
• Anshelevich IV, Prutkin AF, Rubin AI, et al. Primenenie nitroglitserina v kompleksnom lechenii kardiogennogo shoka u bol'nykh infarktom miokarda [Use of nitroglycerin in the complex treatment of cardiogenic shock in patients with myocardial infarction]. Kardiologiia. 1988;28(4):87–89.
   PubMedGoogle Scholar
• Korewicki J, Ostrzycki A, Opolski G. Własne doświadczenia w leczeniu wstrzasu kardiogennego w przebiegu świezego zawału serca dopamina i nitroprusydkiem sodu [Our experience with the treatment of cardiogenic shock in recent myocardial infarction with dopamine and sodium nitroprusside]. Kardiol Pol. 1984;27(5):345–351.
   PubMedGoogle Scholar
• Trojnar R, Kutarski A, Kedra WA, et al. Zastosowanie dobutaminy w leczeniu wstrzasu zawałowego [Use of dobutamine in the treatment of post-infarction shock]. Wiad Lek. 1983;36(7):531.
   PubMedGoogle Scholar
• Meissner A, Schmelzle T, Simon R. Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin [Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine. Z Kardiol. 1996;85(11):839–846.
   PubMedGoogle Scholar
• Wang GJ, Guo YJ, Hou J, et al. Comparison of the effect of dopamine and norepinephrine on cardiogenic shock. Chin J Pract Med. 2011;38:75–76.
   Google Scholar
• Qiu HX, Lin HL, Gu Y, et al. Comparison of dopamine and norepinephrine on treating patients with cardiogenic shock caused by coronary heart disease. Chin J Mod Drug Appl. 2013;7:139–140.
   Google Scholar
• He YH, Chen L, Jiao YL, et al. The contrast between dopamine and norepinephrine in the treatment of cardiogenic shock. Northern Pharma. 2014;2:51.
   Google Scholar
• Gu XF. Contrastive analysis of the therapeutic effect of IABP with dopamine and norepinephrine for treating acute myocardial infarction with cardiogenic shock. Chin J Mod Drug Appl. 2014;13:98–99.
   Google Scholar
• Tan ZH. The comparison of dopamine and norepinephrine for treating cardiogenic shock. Mod Diagn Treat. 2016;27:67–68.
   Google Scholar
• Xiong RC, Yu Z, Sun J, et al. Efficacy of dopamine and norepinephrine in patients with cardiogenic shock. Chin J Mult Organ Dis. 2016;15:919–922.
   Google Scholar
• Li JD, Liu LX, Guo M. Effects of norepinephrine and dopamine on haemodynamics and tissue perfusion in patients with cardiogenic shock. Med Theory Pract. 2015;28:3171–3173.
   Google Scholar
• Jin X. The comparison between dopamine and norepinephrine in shock. Chin Tradit Med Technol. 2014;1:186.
   Google Scholar
• Francis GS, Sharma B, Hodges M. Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse. Am Heart J. 1982;103(6):995–1000.
   PubMed Web of Science ®Google Scholar
• Fowler MB, Timmis AD, Crick JP, et al. Comparison of haemodynamic responses to dobutamine and salbutamol in cardiogenic shock after acute myocardial infarction. Br Med J (Clin Res Ed). 1982;284(6309):73–76.
   PubMedGoogle Scholar
• Timmis AD, Fowler MB, Chamberlain DA. Comparison of haemodynamic responses to dopamine and salbutamol in severe cardiogenic shock complicating acute myocardial infarction. Br Med J (Clin Res Ed). 1981;282(6257):7–9.
   PubMedGoogle Scholar
• Richard C, Ricome JL, Rimailho A, et al. Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock. Circulation. 1983;67(3):620–626.
   PubMed Web of Science ®Google Scholar
• Klocke RK, Mager G, Kux A, et al. Effects of a twenty-four-hour milrinone infusion in patients with severe heart failure and cardiogenic shock as a function of the hemodynamic initial condition. Am Heart J. 1991;121(6 Pt 2):1965–1973.
   PubMed Web of Science ®Google Scholar
• Russ MA, Prondzinsky R, Carter JM, et al. Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan. Crit Care Med. 2009;37(12):3017–3023.
   PubMed Web of Science ®Google Scholar
• Delle Karth G, Buberl A, Geppert A, et al. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand. 2003;47(10):1251–1256.
   PubMed Web of Science ®Google Scholar
• Inglessis I, Shin JT, Lepore JJ, et al. Hemodynamic effects of inhaled nitric oxide in right ventricular myocardial infarction and cardiogenic shock. J Am Coll Cardiol. 2004;44(4):793–798.
   PubMed Web of Science ®Google Scholar
• R R, Jr, Tesarová J, Pechman V, et al. The effects of short-term norepinephrine up-titration on hemodynamics in cardiogenic shock. Physiol Res. 2010;59(3):373–378.
   PubMed Web of Science ®Google Scholar
• van Diepen S, Reynolds HR, Stebbins A, et al. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. Crit Care Med. 2014;42(2):281–288.
   PubMed Web of Science ®Google Scholar
• Cotter G, Kaluski E, Blatt A, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation. 2000;101(12):1358–1361.
   PubMed Web of Science ®Google Scholar
• Russ MA, Prondzinsky R, Christoph A, et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med. 2007;35(12):2732–2739.
   PubMed Web of Science ®Google Scholar
• Jolly S, Newton G, Horlick E, et al. Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction. Am J Cardiol. 2005;96(12):1617–1620.
   PubMed Web of Science ®Google Scholar
• Sicignano A, Bellato V, Riboni A, et al. Enoximone in infusione continua nel trattamento dell' ischemia miocardica acuta con sindrome da bassa gittata [Continuous infusion of enoximone in the treatment of acute myocardial ischemia with low output syndrome]. Minerva Anestesiol. 1994;60(3):109–113.
   PubMedGoogle Scholar
• Bussmann WD, Wehrheim HG. Therapie des kardiogenen schocks mit dobutamin und nitroglycerin [Therapy of cardiogenic shock with dobutamine and nitroglycerin. Dtsch Med Wochenschr. 2008;108(34):1273–1280.
   Google Scholar
• Vincent JL, Léon M, Berré J. The role of enoximone in the treatment of cardiogenic shock. Cardiology. 1990;77(3):21–33.
   Web of Science ®Google Scholar
• Myburgh JA, Higgins A, Jovanovska A, et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008;34(12):2226–2234.
   PubMed Web of Science ®Google Scholar
• Ichai C, Soubielle J, Carles M, et al. Comparison of the renal effects of low to high doses of dopamine and dobutamine in critically ill patients: a single-blind randomized study. Crit Care Med. 2000;28(4):921.
   PubMed Web of Science ®Google Scholar
• Morici N, Oliva F, Ajello S, et al. Management of cardiogenic shock in acute decompensated chronic heart failure: The ALTSHOCK phase II clinical trial. Am Heart J. 2018;204:196–201.
   PubMed Web of Science ®Google Scholar
• Salem R, Mebazaa A. Nitric oxide inhibition rapidly increases blood pressure with no change in outcome in cardiogenic shock: the TRIUMPH trial. Crit Care. 2007;11(3):136.
   PubMed Web of Science ®Google Scholar
• De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779–789.
   PubMed Web of Science ®Google Scholar
• Levy B, Perez P, Perny J, et al. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med. 2011;39(3):450–455.
   PubMed Web of Science ®Google Scholar
• Levy B, Clere-Jehl R, Legras A, et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2018;72(2):173–182.
   PubMed Web of Science ®Google Scholar
• García-González MJ, Domínguez-Rodríguez A, Ferrer-Hita JJ, et al. Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail. 2006;8(7):723–728.
   PubMed Web of Science ®Google Scholar
• Dominguez-Rodriguez A, Samimi-Fard S, Garcia-Gonzalez MJ, et al. Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty. Int J Cardiol. 2008;128(2):214–217.
   PubMed Web of Science ®Google Scholar
• Samimi-Fard S, García-González MJ, Domínguez-Rodríguez A, et al. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. Int J Cardiol. 2008;127(2):284–287.
   PubMed Web of Science ®Google Scholar
• Fuhrmann JT, Schmeisser A, Schulze MR, et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2008;36(8):2257–2266.
   PubMed Web of Science ®Google Scholar
• Husebye T, Eritsland J, Müller C, et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail. 2013;15(5):565–572.
   PubMed Web of Science ®Google Scholar
• Cotter G, Kaluski E, Milo O, et al. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J. 2003;24(14):1287–1295.
   PubMed Web of Science ®Google Scholar
• Dzavík V, Cotter G, Reynolds HR, et al. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur Heart J. 2007;28(9):1109–1116.
   PubMed Web of Science ®Google Scholar
• Alexander JH, Reynolds HR, Stebbins AL, et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007;297(15):1657–1666.
   PubMed Web of Science ®Google Scholar
• Karami M, Hemradj VV, Ouweneel DM, et al. Vasopressors and inotropes in acute myocardial infarction related cardiogenic shock: a systematic review and meta-analysis. J Clin Med. 2020;9(7):2051. Published 2020 Jun 30.
   Web of Science ®Google Scholar
• Tarvasmäki T, Lassus J, Varpula M, et al. Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. Crit Care. 2016;20(1):208.
   PubMedGoogle Scholar
• Morici N, Sacco A, Oliva F, et al. Epinephrine for acute decompensated heart failure and low output state: friend or foe? Int J Cardiol. 2011;149(3):384–385.
   PubMed Web of Science ®Google Scholar
• Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) clinical trials group. Lancet. 2000;356(9248):2139–2143.
   PubMed Web of Science ®Google Scholar
• Friedrich JO, Adhikari N, Herridge MS, et al. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142(7):510–524.
   PubMed Web of Science ®Google Scholar
• Kellum JA, Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001;29(8):1526–1531.
   PubMed Web of Science ®Google Scholar
• Rui Q, Jiang Y, Chen M, et al. Dopamine versus norepinephrine in the treatment of cardiogenic shock: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2017;96(43):e8402.
   PubMed Web of Science ®Google Scholar
• Port JD, Gilbert EM, Larrabee P, et al. Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart. Circulation. 1990;81(3):929–938.
   PubMed Web of Science ®Google Scholar
• Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877–887.
   PubMed Web of Science ®Google Scholar
• Burgos LM, Seoane L, Furmento JF, et al. Effects of levosimendan on weaning and survival in adult cardiogenic shock patients with veno-arterial extracorporeal membrane oxygenation: systematic review and meta-analysis. Perfusion. 2020;35(6):484–488.
   PubMed Web of Science ®Google Scholar
• López A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32(1):21–30.
   PubMed Web of Science ®Google Scholar
• Vahdatpour C, Collins D, Goldberg S. Cardiogenic shock. J Am Heart Assoc. 2019;8(8):e011991.
   PubMed Web of Science ®Google Scholar
• Zeymer U, Bueno H, Granger CB, et al. Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: a document of the acute cardiovascular care association of the European society of cardiology. Eur Heart J Acute Cardiovasc Care. 2020;9(2):183–197.
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, WRITING COMMITTEE MEMBERS, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–e327.
   PubMed Web of Science ®Google Scholar
• van Diepen S, Thiele H. An overview of international cardiogenic shock guidelines and application in clinical practice. Curr Opin Crit Care. 2019;25(4):365–370.
   PubMed Web of Science ®Google Scholar
• He B, Kong L, Ge J. Cardiogenic shock: dopamine or norepinephrine? It's a question. Cardiol Plus. 2017;2:1–4.
   Google Scholar
• Verhagen AP, de Vet HC, de Bie RA, et al. The art of quality assessment of RCTs included in systematic reviews. J Clin Epidemiol. 2001;54(7):651–654.
   PubMed Web of Science ®Google Scholar
• Chalmers TC, Celano P, Sacks HS, et al. Bias in treatment assignment in controlled clinical trials. N Engl J Med. 1983;309(22):1358–1361.
   PubMed Web of Science ®Google Scholar
• Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609–613.
   PubMed Web of Science ®Google Scholar
• Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408–412.
   PubMed Web of Science ®Google Scholar
• Freiman JA, Chalmers TC, Smith H, Jr, et al. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med. 1978;299(13):690–694.
   PubMed Web of Science ®Google Scholar
• Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994;272(2):122–124.
   PubMed Web of Science ®Google Scholar
• Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869–23. Published 2010 Mar
   PubMed Web of Science ®Google Scholar
• Jentzer JC, van Diepen S, Barsness GW, et al. Cardiogenic shock classification to predict mortality in the cardiac intensive care unit. J Am Coll Cardiol. 2019;74(17):2117–2128.
   PubMed Web of Science ®Google Scholar
• Thayer KL, Zweck E, Ayouty M, et al. Invasive hemodynamic assessment and classification of in-hospital mortality risk among patients with cardiogenic shock. Circ Heart Fail. 2020;13(9):e007099.
   PubMed Web of Science ®Google Scholar
• Jentzer JC, Baran DA, van Diepen S, et al. Admission Society for Cardiovascular Angiography and Intervention shock stage stratifies post-discharge mortality risk in cardiac intensive care unit patients. Am Heart J. 2020;219:37–46.
   PubMed Web of Science ®Google Scholar
• Schrage B, Dabboura S, Yan I, et al. Application of the SCAI classification in a cohort of patients with cardiogenic shock. Catheter Cardiovasc Interv. 2020;96(3):E213–E219.
   PubMed Web of Science ®Google Scholar
• Baran DA, Long A, Badiye AP, et al. Prospective validation of the SCAI shock classification: Single center analysis. Catheter Cardiovasc Interv. 2020;96(7):1002–1339.
   Web of Science ®Google Scholar
• Pareek N, Dworakowski R, Webb I, et al. SCAI cardiogenic shock classification after out of hospital cardiac arrest and association with outcome. Catheter Cardiovasc Interv. 2021;97(3):E288–E297. https://doi.org/10.1002/ccd.28984.
   PubMed Web of Science ®Google Scholar
• Hanson ID, Tagami T, Mando R, et al. SCAI shock classification in acute myocardial infarction: insights from the National Cardiogenic Shock Initiative [published online ahead of print, 2020 Jul. Catheter Cardiovasc Interv. 2020;96(6):1110–1137.
   PubMed Web of Science ®Google Scholar
• Garan AR, Kanwar M, Thayer KL, et al. Complete hemodynamic profiling with pulmonary artery catheters in cardiogenic shock is associated with lower in-hospital mortality. JACC Heart Fail. 2020;8(11):903–913.
   PubMed Web of Science ®Google Scholar